The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neoadjuvant chemoradiotherapy with sequential ipilimumab and nivolumab in rectal cancer (CHINOREC): A prospective randomized, open-label, multicenter, phase II clinical trial.
 
Johannes Laengle
Research Funding - Bristol-Myers Squibb
 
Irene Kuehrer
No Relationships to Disclose
 
Dietmar Pils
Research Funding - Boehringer Ingelheim
 
Julijan Kabiljo
No Relationships to Disclose
 
Judith Stift
No Relationships to Disclose
 
Friedrich Herbst
Consulting or Advisory Role - Afferent Pharmaceuticals
 
Bernhard Dauser
No Relationships to Disclose
 
Matthias Monschein
No Relationships to Disclose
 
Peter Razek
No Relationships to Disclose
 
Stefanie Haegele
No Relationships to Disclose
 
Wolfgang Huller
Honoraria - Biomedica; Boehringer Ingelheim; Roche
Consulting or Advisory Role - Roche
Travel, Accommodations, Expenses - Biocartis
 
Reinhold Fuegger
No Relationships to Disclose
 
Hans Geinitz
No Relationships to Disclose
 
Andreas L. Petzer
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Clemens Bitterman
Speakers' Bureau - Intuitive Surgical
Travel, Accommodations, Expenses - Intuitive Surgical
 
Friedrich Laengle
No Relationships to Disclose
 
Dietmar Tamandl
No Relationships to Disclose
 
Joachim Widder
No Relationships to Disclose
 
Rainer Schmid
No Relationships to Disclose
 
Michael Bergmann
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - Boehringer Ingelheim; Bristol-Myers Squibb